Research Papers:

miR-27a-3p targeting RXRα promotes colorectal cancer progression by activating Wnt/β-catenin pathway

Jiangtao Liang, Jianming Tang, Huijuan Shi, Hui Li, Tiantian Zhen, Jing Duan, Lili Kang, Fenfen Zhang, Yu Dong and Anjia Han _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:82991-83008. https://doi.org/10.18632/oncotarget.19635

Metrics: PDF 1792 views  |   HTML 2587 views  |   ?  


Jiangtao Liang1,*, Jianming Tang1,*, Huijuan Shi1,*, Hui Li1, Tiantian Zhen1, Jing Duan1, Lili Kang1, Fenfen Zhang1, Yu Dong1 and Anjia Han1

1Department of Pathology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China

*These authors have contributed equally to this work

Correspondence to:

Anjia Han, email: [email protected]

Keywords: miR-27a-3p, RXRα, Wnt/β-catenin pathway, colorectal cancer

Received: March 22, 2017    Accepted: July 06, 2017    Published: July 26, 2017


This study aimed to elucidate how miR-27a-3p modulates the Wnt/β-catenin signaling pathway to promote colorectal cancer (CRC) progression. Our results showed that the expression of miR-27a-3p was up-regulated in CRC and closely associated with histological differentiation, clinical stage, distant metastasis and CRC patients’ survival. miR-27a-3p mimic suppressed apoptosis and promoted proliferation, migration, invasion of CRC cells in vitro and in vivo. Whereas miR-27a-3p inhibitor promoted apoptosis and suppressed proliferation, migration, invasion of CRC cells in vitro and in vivo. Furthermore, RXRα was the target gene of miR-27a-3p in CRC. miR-27a-3p expression negatively correlated with RXRα expression in CRC tissues. The underlining mechanism study showed that miR-27a-3p/RXRα/Wnt/β-catenin signaling pathway is involved in CRC progression. In conclusion, our findings first demonstrate that miR-27a-3p is a prognostic and/or potential therapeutic biomarker for CRC patients and RXRα as miR-27a-3p targeting gene plays an important role in activation of the Wnt/β-catenin pathway during CRC progression.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19635